Tuberous Sclerosis Complex
Released: December 28, 2022
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Tuberous Sclerosis Complex Research Program
Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)
The FY23 Defense Appropriations Bill has not been signed into law. Although FY23 funds have not been appropriated for the Tuberous Sclerosis Research Program (TSCRP), the TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.
The FY23 Defense Appropriations Act is anticipated to provide funding for the TSCRP to support innovative, high-impact tuberous sclerosis complex (TSC) research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities. The FY23 TSCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY23 TSCRP must address one or more of the following Focus Areas:
- Understanding, preventing, and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological, behavioral, and surgical interventions
- Strategies for eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of tumor microenvironment, TSC signaling and mTOR-independent pathways
- Preventing, epilepsy, improving treatment, and mitigating neurodevelopmental and adverse outcomes associated with TSC-related seizures
- Developing, assessing, and testing emerging technologies including imaging and molecular therapeutic strategies, such as gene therapy, to improve outcomes in TSC
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Exploration - Hypothesis Development Award||Investigators at or above postdoctoral fellow (or equivalent)||
|Idea Development Award||
Independent investigators at or above the level of Assistant Professor (or equivalent)
Must not have received more than $300,000 in total direct costs for previous or concurrent TSC research as a Principal Investigator (PI) of one or more federally funded, non-mentored peer-reviewed grants. (National Institutes of Health K Awardees are eligible to apply.)
|Clinical Translational Research Award||Independent investigators at or above the level of Assistant Professor (or equivalent)||
A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Thursday, December 29, 2022